De-Escalation of Bone-Targeted Agents for Metastatic Prostate Cancer
by
Brian Younho Hong
1,
Mohammed F.K. Ibrahim
2,
Ricardo Fernandes
2,
Sasha Mazzarello
3,
Brian Hutton
4,
Risa Shorr
5 and
Mark Clemons
6,* 
1
MD Program, Faculty of Medicine University of Ottawa, Ottawa, ON, Canada
2
Division of Medical Oncology and Department of Medicine University of Ottawa, Ottawa, ON, Canada
3
Ottawa Hospital Research Institute, Ottawa, ON, Canada
4
Department of Epidemiology and Community Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada
5
The Ottawa Hospital Ottawa, Ottawa, ON, Canada
6
Division of Medical Oncology and Department of Medicine University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2016, 23(1), 77-78; https://doi.org/10.3747/co.23.2913
Submission received: 2 November 2015
/
Revised: 4 December 2015
/
Accepted: 6 January 2016
/
Published: 1 February 2016
Abstract
Despite advances in therapy, bone remains the most common site of prostate cancer recurrence [...]
Share and Cite
MDPI and ACS Style
Hong, B.Y.; Ibrahim, M.F.K.; Fernandes, R.; Mazzarello, S.; Hutton, B.; Shorr, R.; Clemons, M. De-Escalation of Bone-Targeted Agents for Metastatic Prostate Cancer. Curr. Oncol. 2016, 23, 77-78. https://doi.org/10.3747/co.23.2913
AMA Style
Hong BY, Ibrahim MFK, Fernandes R, Mazzarello S, Hutton B, Shorr R, Clemons M. De-Escalation of Bone-Targeted Agents for Metastatic Prostate Cancer. Current Oncology. 2016; 23(1):77-78. https://doi.org/10.3747/co.23.2913
Chicago/Turabian StyleHong, Brian Younho, Mohammed F.K. Ibrahim, Ricardo Fernandes, Sasha Mazzarello, Brian Hutton, Risa Shorr, and Mark Clemons. 2016. "De-Escalation of Bone-Targeted Agents for Metastatic Prostate Cancer" Current Oncology 23, no. 1: 77-78. https://doi.org/10.3747/co.23.2913
